Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting. […]